

Results of General Meeting

Neurotech International Limited (ASX: NTI) ("Neurotech" or "the Company") today held a General Meeting of Members at the offices of BDO Australia, Level 9, Mia Yellagonga Tower 2, 5 Spring St, Perth WA 6000.

All resolutions were determined by a poll.

The outcome of each resolution put to shareholders at the General Meeting is set out in the Annexure which accompanies this release.

Authority

This announcement has been authorised for release by the Company Secretary of Neurotech International Limited.

Investors:

Dr Thomas Duthy

Executive Director

td@neurotechinternational.com

+61 (0)402 493 727

About Neurotech

Neurotech International Limited (ASX:NTI) is a clinical-stage biopharmaceutical development company focused predominately on paediatric neurological disorders. Neurotech has completed a Phase I/II clinical trial in Autism Spectrum Disorder (ASD), which demonstrated excellent safety and efficacy results at 28 days, 20 weeks and 52 weeks of treatment with NTI164. The Company commenced Phase II/III randomised, double-blind, placebo-controlled clinical trial in ASD in Q4 CY2022. Neurotech is also conducting additional Phase I/II trials in Paediatric Autoimmune Neuropsychiatric Disorders Associated with Streptococcal Infections (PANDAS) and Paediatric Acute-Onset Neuropsychiatric Syndrome (PANS), collectively PANDAS/PANS, along with Rett Syndrome and Cerebral Palsy during CY2023. Neurotech is also commercialising Mente, the world's first home therapy that is clinically proven to increase engagement and improve relaxation in autistic children with elevated Delta band brain activity.

For more information about Neurotech please visit <http://www.neurotechinternational.com>.

Disclosure of Proxy Votes

Neurotech International Limited

General Meeting

Thursday, 01 June 2023



Automic

GPO Box 5193, Sydney, NSW 2001

P 1300 288 664 (aus) or +61 (0)2 9698 5414 (world)

F +61 (0)2 8583 3040 E hello@automic.com.au

ABN 27 152 260 814

In accordance with section 251AA of the Corporations Act 2001, the following information is provided in relation to resolutions put to members at the meeting.

			Proxy Votes				Poll Results		
Resolution	Decided by Show of Hands (S) or Poll (P)	Total Number of Proxy Votes exercisable by proxies validly appointed	FOR	AGAINST	ABSTAIN	PROXY'S DISCRETION	FOR	AGAINST	ABSTAIN
1 Ratification of Placement Shares issued under LR7.1A (November)	P	50,576,667	43,008,049 85.04%	284,613 0.56%	0	7,284,005 14.40%	52,292,054 99.46%	284,613 0.54%	0
2 Ratification of Placement Shares issued under LR7.1 (November)	P	50,576,667	43,008,049 85.04%	284,613 0.56%	0	7,284,005 14.40%	52,292,054 99.46%	284,613 0.54%	0
3 Ratification of Placement Shares issued under LR7.1 (December)	P	50,576,667	43,008,049 85.04%	284,613 0.56%	0	7,284,005 14.40%	52,292,054 99.46%	284,613 0.54%	0
4 Ratification of Placement Options	P	50,576,667	42,808,049 84.64%	484,613 0.96%	0	7,284,005 14.40%	52,092,054 99.08%	484,613 0.92%	0
5 Ratification of Options to the Joint Lead Managers	P	146,340,073	138,571,455 94.69%	484,613 0.33%	0	7,284,005 4.98%	147,855,460 99.67%	484,613 0.33%	0
6 Issue of Options to Dr Alexandra Andrews	P	140,929,860	140,430,484 99.65%	320,307 0.23%	0	179,069 0.13%	140,609,553 99.77%	320,307 0.23%	0
7 Issue of Options to the estate of the late Professor Allan Cripps AO	P	140,749,860	140,250,484 99.65%	320,307 0.23%	0	179,069 0.13%	140,429,553 99.77%	320,307 0.23%	0



			Proxy Votes				Poll Results		
Resolution	Decided by Show of Hands (S) or Poll (P)	Total Number of Proxy Votes exercisable by proxies validly appointed	FOR	AGAINST	ABSTAIN	PROXY'S DISCRETION	FOR	AGAINST	ABSTAIN
8 Issue of Options to Max Capital	P	146,340,073	138,470,955 94.62%	557,613 0.38%	0	7,311,505 5.00%	147,782,460 99.62%	557,613 0.38%	0

